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Abstract
A significant progress in the treatment of heart failure occurred during the last 20 years. These
advances were associated with the introduction and subsequent widespread use of angiotensin-
-converting enzyme inhibitors and beta blockers, but also with progress in device therapy and
cardiac surgery. Overall, prognosis in patients with severe heart failure is similar to outcomes
reported in multicenter randomized clinical trials, such as CONSENSUS, CIBIS II, MERIT-HF,
and COPERNICUS. In 2003–2007, a registry of patients with severe heart failure was estab-
lished in Poland (POLKARD-HF) that included all patients initially considered candidates
for heart transplantation (HTX). Mean duration of follow-up was 601 days (range 1-1462 days).
One-year mortality (defined as death or super-urgent HTX) was 20% and differed from data
presented by Stewart (2001). In addition, patient survival in the POLKARD-HF registry
depending on the New York Heart Association (NYHA) class changed significantly in com-
parison to outcomes reported in the late 1980s. However, one-year mortality among NYHA
class IV patients is still high and exceeds 50%. As reported in the POLKARD-HF registry, one-
-year risk of death among patient who underwent elective HTX was about 20%, and 3-year risk
was about 22%, significantly different from the risk of death among medically treated patients
with heart failure. These results are similar to other European data and warrant reconsidera-
tion of appropriatness of HTX in elective patients (UNOS 2 status). Undoubtedly, NYHA class IV
patients are candidates for HTX and should remain under specialist care in cardiac trans-
plantation centers, and HTX should be performed in this group when indications for this
procedure become urgent (UNOS 1 and 1a status).
A specialized system of care for patients with severe heart failure should be created in Poland,
particularly for patients referred for HTX. There is also an urgent need to introduce modern
systems of mechanical cardiac support (left ventricular assist devices, LVAD) that would allow
precise determination of indications and contraindications to HTX and create opportunities
for long-term treatment. (Cardiol J 2009; 16, 6: 493–499)
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In 2001, Stewart et al. [1] noted that the 5-year
survival in patients with heart failure was worse
than in patients with most cancers. One-year
survival with heart failure was less than 60%, and
4-year survival was about 35%, thus heart failure
was dubbed “more malignant then cancer”.
During the last 20 years, a significant progress
in the treatment of heart failure occurred, related
not only to pharmacotherapy, but also to device
therapy and invasive treatment [2–6]. These ad-
vances in therapy resulted in improved prognosis
and quality of life of patients with heart failure, includ-
ing those with severe heart failure. In patients with
the New York Heart Association (NYHA) class IV
patients who participated in the CONSENSUS
study, treatment with enalapril was associated with
a relative reduction of the risk of death by 40% at
6 months and by 31% at one year of treatment com-
pared to the control group [4, 6]. Another advance
in pharmacotherapy of heart failure was the intro-
duction of beta1-adrenergic receptor antagonists
(beta-blockers). A metaanalysis of CIBIS II, MER-
IT HF, and COPERNICUS studies showed a rela-
tive reduction of the risk of death by 33% in NYHA
class III patients and 31% in NYHA class IV patients
[5, 7, 8]. Based on these studies, it may be theore-
tically assumed that one-year mortality in patients
with severe heart failure receiving conventional
treatment (i.e. with digitalis and diuretics) would
be 52%. Treatment with a angiotensin-converting
enzyme (ACE) inhibitor should lower this mortality
rate to 36%, and additional use of an aldosterone
antagonist would result in lowering one-year
mortality to 18%. Full treatment according to
current guidelines should lower one-year mortali-
ty among patients with severe heart failure (NYHA
class III–IV) to about 12% [9].
These estimations have been confirmed in
numerous contemporary epidemiological studies. In
the United States, one-year mortality among pa-
tients with severe heart failure in 1994–1997 was
about 20%, and 3-year mortality was about 67%. In
1999–2001, corresponding mortality rates were
12% and 79%, respectively. The effects of treat-
ment depend on the age of patients. Prognosis in
patients aged less than 75 years is similar to that
found in the above mentioned studies from the
United States but it is significantly worse among
patients over 75 years of age. One-year mortality
among patients aged more than 75 years is about
37%, and 3-year mortality is about 60% [10–12].
Further considerations, as related to the main
topic of this paper, will be restricted to patients with
severe heart failure under 65 years of age. This is
the population of patients primarily considered for
heart transplantation (HTX).
Outcomes after HTX improved substantially
with the introduction of modern immunosuppresive
treatment, mainly with calcineurin inhibitors such
as cyclosporine. Data from the International Socie-
ty for Heart and Lung Transplantation (ISHLT)
registry show that in 1993–2000, survival at 1, 3, 5,
and 10 years was about 85%, 75%, 70%, and 50%,
respectively [13, 14].
Potential candidates to HTX (based on [15]) are
patients under 65 years of age with heart failure who
fulfill the following criteria despite optimal treat-
ment:
— NYHA class III–IV heart failure symptoms;
— episodes of hypervolemia or reduced cardiac
output at rest;
— ejection fraction reduced below 30%;
— Doppler evidence of impaired left ventricular
diastolic filling;
— high left ventricular end-diastolic pressure or
mean pulmonary capillary wedge pressure
> 19 mm Hg and mean right atrial pressure
> 12 mm Hg;
— elevated level of N-terminal propeptide of
the brain natriuretic peptide (NT-proBNP)
(> 2000 pg/mL);
— frequent hospitalizations due to heart failure
during the last 6 months, requiring administra-
tion of catecholamines;
and in whom functional studies show:
— inability to exercise (NYHA class IV);
— 6-minute walking distance of less than 300 m;
— maximal oxygen uptake (VO2max) of less than
12–14 mL/kg/min.
Extrapolating data from the ISHLT registry in
1999–2001, approximately 850 patients in Poland
should qualify for HTX during 3 years (in 2003–
–2005, in fact 335 patients actually qualified), includ-
ing 50% of patients qualifying for an urgent trans-
plantation (about 20% patients in Poland).
The Poltransplant criteria for an urgent HTX
are as follows:
— mechanical cardiac support due to acute circu-
latory decompensation;
— continuous mechanical ventilation;
— severe refractory arrhythmia;
— acute heart failure within 7 days after HTX.
Poltransplant HTX qualifying criteria are more
liberal than the UNOS or Eurotransplant criteria but
do not account data regarding prognosis in these
patients. This is an important issue due to a differ-
ent system of care for patients qualifying for HTX
in Poland compared to other European countries
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and the United States. In Poland, patients qualify-
ing for an urgent HTX who present to transplanta-
tion centers are usually critically ill. In these
circumstances, precise determination of indications
and contraindications for HTX is sometimes diffi-
cult. This is probably the main reason of worse HTX
outcomes in these patients compared to the Unit-
ed States and Western Europe. Systems of mechan-
ical cardiac support available in Poland that might
improve diagnostic work-up and prognosis in pa-
tients qualifying for an urgent HTX may be used
only for a relatively brief period (about 2–3 months)
and only in hospitalized patients. A larger group
(about 80% of patients in Poland) that is very het-
erogeneous in terms of clinical characteristics and
prognosis includes patients qualifying for an elec-
tive HTX.
In 2003–2007, a registry of patients with severe
heart failure initially considered as candidates for
HTX (POLKARD-HF) was set up in Poland using
a grant from the Polish Ministry of Health [16]. The
main objective of this program was to evaluate prog-
nosis in patients with severe heart failure prior to
HTX and also after HTX in patients who eventual-
ly underwent transplantation. An additional goal was
to identify risk factors for death or an urgent HTX.
Results of this registry may be used to extend
previous data and define more precise criteria
allowing qualification for HTX. Overall, 983 patients
were included in the registry in four centers per-
forming HTX in Poland in 2003–2007 (Table 1).
Most of these patients (n = 658) qualified for
HTX and during the period covered by the regis-
try, transplantation was actually performed in
325 patients. Patients included in the registry were
young (mean age 49 ± 11 years), had advanced
heart failure with ejection fraction of 21.6 ± 8%, low
systemic blood pressure (102 ± 15 mm Hg), and
showed evidence of moderate pulmonary hyperten-
sion. Laboratory tests showed elevated levels of
high-sensitivity C-reactive protein (hsCRP) (mean
3.0 mg/L, range 0.03–347.0), and NT-proBNP (mean
2294 pg/mL, range 28–46128), while mean sodium
level was 136 ± 4 mEq/L. The mean duration of
follow-up was 601 days (range 1–1462) (Fig. 1).
Survival of patients with severe heart failure
or undergoing an urgent HTX was about 80% at one
year and 67% at 3 years of follow-up, and thus was
substantially higher than among patients with heart
failure included in the study by Stewart et al. [1] (56%
and 34%, respectively) (Fig. 2).
Analysis of outcomes in patients with heart
failure depending on the NYHA functional class also
showed significant improvement compared to the
studies performed in the late 80s [12–14, 16, 17]. Of
note, prognosis among NYHA class IV patients is still
very poor, as one-year mortality in this group (defined
as death or a very urgent HTX) was 50% (Table 2).
Based on Kaplan-Meier survival analysis, the
following significant prognostic factors were iden-
tified: pulmonary artery systolic pressure, mean
pulmonary capillary wedge pressure, left ventricu-
lar ejection fraction, NYHA functional class, low
systemic blood pressure, hsCRP level, NT-proBNP
level, body mass index, sodium level, and Heart
Failure Survival Score (HFSS) proposed by Aaron-
son et al. (Table 3) [17, 18].
In multivariate analysis, after removal of NYHA
functional class and HFSS as dependent variables,
the following variables remained independent risk
factors for death or a very urgent HTX: NT-proBNP
level ≥ 4302 pg/mL and sodium level £ 135 mEq/L.
Of note, HFSS calculated using the Aaronson for-
mula, incorporating clinical, functional, and bio-
Table 1. Characteristics of patients with severe
heart failure included in the POLKARD-HF registry
in 2003–2007 [16].
Variable N Mean ± SD
*Median [Min–Max]
Age (years) 983 49.38±11.245
Body mass [kg] 982 77.9±15.42
Height [cm] 980 172.8±9.71
BMI [kg/m2] 979 25.982±4.5004
EF (%) 978 21.6±8.13
LVEDD [mm] 953 71.93±10.472
LVESD [mm] 905 60.30±13.217
HR [bpm] 962 78.3±15.80
Systolic BP [mm Hg] 975 102.6±14.97
Diastolic BP [mm Hg] 975 67.0±11.12
PASP [mm Hg] 629 44.9±17.41
Mean PCWP [mm Hg] 695 20.8±9.41
CI [L/min/m2] 530 1.95±0.854
PVR [Wood Units] 64 3.13±2.392
PG [mm Hg] 654 10.61±6.677
hsCRP [mg/L]* 679 3.00 [0.03–347.00]
NT-proBNP [pg/mL]* 694 2294.5 [28.0–46128.0]
VO2max [mL/kg/l] 687 13.05±4.345
HFSS 952 7.7±0.98
Na [mEq/L] 973 136.4±4.41
BMI — body mass index; EF — ejection fraction; LVEDD — left ventri-
cular end-diastolic diameter; LVESD — left ventricular end-systolic
diameter; HR — heart rate; BP — blood pressure; PASP — pulmonary
artery systolic pressure; PCWP — pulmonary capillary wedge pressure;
CI — cardiac index; PVR — pulmonary vascular resistance; PG — pul-
monary gradient; hsCRP — high sensitivity C-reactive protein;
NT-proBNP — N-terminal propeptide of the brain natriuretic peptide;
VO2max — maximal oxygen uptake; HFSS — Heart Failure Survival
Score; Na — sodium
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Figure 1. Probability of survival of patients with heart failure [1, 16].
Figure 2. Probability of survival of patients with heart failure depending on the New York Heart Association (NYHA)
functional class (____ Kaplan-Meier curves for patients with heart failure included in the POLKARD-HF registry,
.... Kaplan-Meier curves for patients with heart failure based on data from Massie B et al. Circulation, 1987; 75: 11–19).
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chemical parameters, is routinely evaluated in pa-
tients with heart failure and has a very high prog-
nostic importance. Values of 5.5–7.19 are associat-
ed with a high risk of death, values of 7.2–9.09 with
a moderate risk, and values of 8.1–10.49 with a low
risk of death. In the POLKARD-HF registry of pa-
tients with severe heart failure, mean HFSS was
7.7 ± 0.98, and in the highest risk group (with one-
year mortality of 50%) it was £ 7.19 [18–22].
Patients entering the registry were general-
ly treated according to the current guidelines,
with 90–100% of patients receiving beta1-adren-
ergic receptor antagonists, ACE inhibitors and
diuretics, and about 80% of patients treated with
aldosterone antagonists. However, the doses
used were much lower than those recommended
in the current guidelines, as the doses of standard
drugs, except diuretics, were only about 25% of
the recommended dosage on admission (and en-
try into the registry), and about 50% at hospital
discharge (unpublished results based on patients
entered into the registry in the Institute of Car-
diology).
As most patients were not initially receiving
adequate treatment, final evaluation of indications
for HTX was done, if possible, at 3 months after the
entry into the registry, thus allowing time for treat-
ment optimalization.
Patients scheduled for elective HTX remained
under the ambulatory care until transplantation in
the centers participating in the registry. Patients
at higher risk of HTX, mainly with reversible (re-
active) pulmonary hypertension, were evaluated
every 3 months, and the remaining patients were
evaluated every 6 months. Patients with heart fail-
ure who were considered potential candidates but
were not scheduled for elective HTX, also remained
under the ambulatory care in the centers partici-
pating in the registry.
Three-year outcomes in patients who under-
went elective HTX differed from outcomes in med-
ically treated patients, mainly due to deaths occur-
ring in the first days or weeks after HTX (Fig. 3).
Our experience and data collected in other cen-
ters suggest that it is questionable whether HTX
should be performed at all in patients scheduled for
Table 2. Risk factors for death of an urgent heart transplantation (values are upper or lower limits of
terciles determined as statistically significant in the Kaplan-Meier analysis); POLKARD-HF [16].
YES NO
Pulmonary artery systolic pressure ≥ 50 mm Hg Pulmonary vascular resistance
Pulmonary capillary wedge pressure ≥ 25 mm Hg Pulmonary gradient
Left ventricular ejection fraction £ 17% Cardiac index
NYHA functional class IV VO2max
Systolic blood pressure £ 90 mm Hg Diastolic blood pressure
hsCRP 6.5 mg/L Etiology of heart failure
NT-proBNP ≥ 4302 pg/mL Sex
HFSS £ 7.19
Sodium £ 135 mEq/L
Body mass index £ 23.8 kg/m2
NYHA — New York Heart Association; hsCRP — high sensitivity C-reactive protein; NT-proBNP — N-terminal propeptide of the brain natriuretic
peptide; HFSS — Heart Failure Survival Score; VO2max — maximal oxygen uptake.
Table 3. Variables included in the Heart Failure Survival Score (HFSS) proposed by Aaronson et al. [18, 26].
Ischemic heart disease (yes = 1, no = 0) (…… x  0.6931) = +
Intraventricular conduction distrubances (yes = 1, no = 0) (…… x  0.6083) = +
Ejection fraction (%) (…… x  0.0464) = +
Heart rate [bpm] (…… x  0.0221) = +
Sodium level [mEq/L] (…… x – 0.0470) = +
Mean arterial pressure [mm Hg] (…… x – 0.0255) = +
Maximal oxygen uptake (VO2max) (…… x – 0.546) = +
HFSS = ……………...........
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3. Patients scheduled for elective HTX in whom
low HFSS value or high NT-proBNP level is
demonstrated, or who require recurrent hospi-
talizations due to cardiac decompensation de-
spite apparently optimal treatment, should
undergo an urgent HTX.
4. Top priorities should include immediate imple-
mentation of modern systems of mechanical
cardiac support and establishing highly specia-
lized centers caring for patients with severe
heart failure.
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